BioNexus Gene Lab Corp
BGLC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BGLC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BGLC
BioNexus Gene Lab Corp (BGLC) is a diagnostics and life sciences company focused on commercializing the VitaGuard™ MRD platform in Southeast Asia through its Fidelion subsidiary, while maintaining a clean capital structure with no debt.
Key risk: Low revenue and net loss
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
BioNexus Gene Lab Corp (BGLC) is a diagnostics and life sciences company focused on commercializing the VitaGuard™ MRD platform in Southeast Asia through its Fidelion subsidiary, while maintaining a clean capital structure with no debt.
- Cash & equivalents of $2.4M as of 2026-06-30 [sec].
- Total revenue of $0.1M and net loss of -$0.3M for the period ended 2026-06-30 [sec].
- Shareholders' equity of $7.5M and total debt of $0.0M as of 2026-06-30 [sec].
- Completed the Fidelion transaction in November 2025, securing exclusive commercialization rights for the VitaGuard™ MRD platform in ASEAN [sec_mda · as of 2026-08-14].
- Achieved full Nasdaq compliance in April 2025 after a 1-for-10 reverse stock split [sec_mda · as of 2026-05-15].
What works
- Clean capital structure with no preferred stock, convertible debt, or high-yield instruments, providing flexibility for growth initiatives [sec_mda · as of 2026-05-15].
- Exclusive commercialization rights for the VitaGuard™ MRD platform in ASEAN, a tumor-agnostic liquid biopsy for minimal residual disease detection [sec_mda · as of 2026-08-14].
- Minimal outstanding debt and a simplified capital structure support operational continuity and potential M&A [sec_mda · as of 2026-05-15].
What to weigh
- Very low revenue of $0.1M as of 2026-06-30, indicating early-stage commercialization [sec].
- Net loss of -$0.3M for the period ended 2026-06-30, reflecting ongoing operating expenses [sec].
- Cash & equivalents of only $2.4M as of 2026-06-30 may limit runway for scaling operations without additional financing [sec].
- Dependence on equity or debt financing to fund operations, as noted in prior filings [sec · filed 2025-02-27].
From the filings
Quoted directly from source documents.
Exclusive commercialization rights for VitaGuard MRD platform in ASEAN
“the Company obtained exclusive, perpetual commercialization rights for the VitaGuard™ MRD platform in ASEAN”
SEC MD&A · August 14, 2026
Full Nasdaq compliance achieved in April 2025
“April 2025: Full Nasdaq compliance achieved, reinforcing market stability and investor confidence.”
SEC MD&A · May 15, 2026
Total liquidity of $3.5 million as of June 30, 2026
“total liquidity of $3.5 million”
SEC MD&A · August 14, 2026
Risks & what to watch (4)›
Key risks
- Low revenue and net loss — Revenue of $0.1M and net loss of -$0.3M as of 2026-06-30 indicate early-stage operations with limited profitability [sec].
- Limited cash runway — Cash & equivalents of $2.4M as of 2026-06-30 may require additional financing to sustain operations and growth [sec].
- Dependence on equity financing — Company intends to raise capital through equity or debt financing, as stated in prior filings [sec · filed 2025-02-27].
- Commercialization execution risk — VitaGuard MRD platform deployment in ASEAN is in early phases; success depends on market adoption and partnerships [sec_mda · as of 2026-08-14].
What to watch
- Progress of VitaGuard™ MRD platform deployment in Southeast Asia, including any partnership or revenue milestones [sec_mda · as of 2026-08-14].
- Cash burn rate and any new financing activities, given $2.4M cash as of 2026-06-30 [sec].
- Updates on Chemrex strategic-development opportunities authorized by the Board [sec_mda · as of 2026-08-14].
- Release of updated corporate website and presentation materials expected in Q3 2026 [sec_mda · as of 2026-08-14].
Sources: SEC filings · SEC MD&A · Generated August 16, 2026 · How we verify sources →
Run BioNexus Gene Lab Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BioNexus Gene Lab Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
22.4 months
D/E 0.12
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$2
| Holder | Shares | Value |
|---|---|---|
| wells fargo & company/mn | 1 | $2 |
Short Interest
as of May 20, 2026- % of float
- 0.5%
- Days to cover
- 2.9
- Shares short
- 9,982
- Daily short volume (Jul 17, 2026)
- 3.8%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BGLC short interestGovernance
Frequently asked questions
What is the AI investment thesis for BioNexus Gene Lab Corp?
BioNexus Gene Lab Corp (BGLC) is a diagnostics and life sciences company focused on commercializing the VitaGuard™ MRD platform in Southeast Asia through its Fidelion subsidiary, while maintaining a clean capital structure with no debt.
Who is the CEO of BioNexus Gene Lab Corp?
Mr. Su-Leng Tan is the chief executive officer of BioNexus Gene Lab Corp (BGLC).
Where is BioNexus Gene Lab Corp headquartered?
BioNexus Gene Lab Corp (BGLC) is headquartered in Kuala Lumpur, Malaysia.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.